IRD — Opus Genetics Share News
0.000.00%
Last trade - 00:00- $317.81m
- $265.20m
- $14.20m
Brief: Ocuphire Pharma Announces First Patient Enrolled In Late-stage Study Of Nyxol In Presbyopia
U.S. STOCKS ON THE MOVE-Moderna, crypto stocks, U.S. banks
U.S. STOCKS ON THE MOVE-Gossamer Bio, Summit Therapeutics, VistaGen
Ocuphire Pharma submits marketing application for eye drug, shares up
Brief: Ocuphire Pharma Announces Submission Of NDA To FDA For Nyxol Eye Drops
U.S. STOCKS ON THE MOVE-Gold, silver, and copper miners
U.S. STOCKS ON THE MOVE-Skywater Technology, First Advantage, solar stocks
U.S. STOCKS ON THE MOVE-Norwegian Cruise, Taskus, Vertex Energy
U.S. STOCKS ON THE MOVE-Lordstown Motors, Ocuphire Pharma, Hims & Hers Health
Ocuphire Pharma up on agreement with FamyGen to develop eye drug
Brief: Ocuphire Pharma Enters Into License Agreement For Development And Commercialization Of Nyxol Eye Drops
Brief: Ocuphire Pharma Announces Financial Results For Q3 2022
Brief: Ocuphire Pharma Receives PDFUA Fee Waiver For Nyxol New Drug Application From FDA
Brief: Ocuphire Pharma Announces Last Patient Completes Final Visit In Zeta-1 Phase 2B 24-Week Trial Of Oral Apx3330 In Diabetic Retinopathy
Brief: Ocuphire Pharma reports Q2 results
Ocuphire Pharma Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Ocuphire Pharma Inc - Issuance Extends Nyxol's U.S. Patent Protection From 2034 Into 2039 For RM Indication
Brief: Ocuphire Pharma To Present New Interim Masked Safety Data For Oral Apx3330 In Diabetics At Annual Macula Society Meeting
NASDAQ RESUMED AT 07:30 AM